

July 26, 2024

General Announcement:

Senju Pharmaceutical Co., Ltd.

Launch of Distribution of RET-700

Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida; hereinafter “Senju”) hereby announces the launch of distribution of RET-700 in Japan, effective immediately (medical device approval number 37B1X10001000060), where the marketing authorization holder is Rexam Co., Ltd. (hereinafter “Rexam”).

RET-700 is an auto ref-topographer equipped with Auto Refract Keratometer, Topographer, Wavefront, Dry eye analysis (optional) and Meibomian glands analysis, as the device is all in one with functionality and operability.

This distribution will be implemented by way of a partnership between Senju and Rexam. Through this alliance, Senju and Rexam will further contribute to people’s ‘health and prosperity by the realization and synergy of Senju’s mission of the “Pursuit of happiness for all people”, and Rexam’s` policy the “Take boldly on any challenge, while putting ourselves in customer’s shoes”.

[Contact details for inquiries]

Medical Device Department, Senju Pharmaceutical Co., Ltd.

3-1-9, Kawara-machi, Chuo-ku, Osaka 541-0048, Japan

Mail: medical-device@senju.co.jp

URL: <https://www.senju.co.jp>